3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Breast Neoplasms
38
Neoplasms
33
Depression
28
Fatigue
24
Prostatic Neoplasms
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
17
Multiple Myeloma
15
Lymphoma, Non-Hodgkin
14
Lymphoma, Mantle-Cell
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Burkitt Lymphoma
14
Lymphoma, B-Cell, Marginal Zone
13
Leukemia, Myeloid, Acute
13
Hodgkin Disease
13
Colorectal Neoplasms
13
Lymphoma, Large-Cell, Immunoblastic
12
Lung Neoplasms
12
Anxiety Disorders
12
Lymphoma
11
Leukemia, Myeloid, Chronic-Phase
11
Blast Crisis
11
Leukemia, Myeloid, Accelerated Phase
10
Recurrence
9
Pain
9
Lymphoma, T-Cell, Cutaneous
9
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
9
Leukemia, Hairy Cell
9
Leukemia
9
Interventions
Exercise
4
Cholecalciferol
4
Nutrition Assessment
3
Gonadotropin-Releasing Hormone
3
Blood Pressure
3
Atorvastatin
3
palbociclib
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
acalabrutinib
2
Vitamin E
2
Social Determinants of Health
2
Rosuvastatin Calcium
2
Metformin
2
Geritol
2
Fish Oils
2
Fatty Acids, Omega-3
2
Ethanol
2
Electrocardiography
2
Educational Status
2
Echocardiography
2
Diet, Mediterranean
2
Blood Specimen Collection
2
Aspirin
2
Antineoplastic Agents
2
Absorptiometry, Photon
2
zanubrutinib
1
xinmailong
1
ribociclib
1
phosphoribosylformylglycinamidine synthetase
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cardiovascular Diseases
×
Therapeutics
×
Clear all
NCT03443635
2022-04-29
CHOP
Tulane University
Phase 1/2
Completed
7,192 enrolled
7 charts